Biogen Inc. Stock
Biogen Inc. Stock
Pros and Cons of Biogen Inc. in the next few years
Pros
Cons
Performance of Biogen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 0.160% | 4.804% | -6.677% | -28.900% | -19.975% | -13.102% | -5.909% |
| Pfizer Inc. | -3.630% | 3.087% | -3.176% | -32.102% | -5.958% | -23.189% | -26.951% |
| Elanco Animal Health Inc. | 0.510% | -1.098% | -15.068% | 35.005% | -8.033% | -52.029% | - |
| AbbVie Inc. | -0.940% | 1.924% | -5.061% | 5.545% | 11.949% | 70.293% | 121.713% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.
Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.
Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.
Comments
News
Why Biogen Stock Leaped Nearly 5% Higher Today
Before market open on Wednesday, Biogen (NASDAQ: BIIB) unveiled its first earnings report of 2024. Happily, the company was far more profitable than many expected it to be, and investors rewarded
Biogen (BIIB) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q1 2024 Earnings CallApr 24, 2024, 8:30 a.m. ET
Operator
Source Fool.com
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311